Locations:
SearchRomosozumab builds more bone than any previous medication
Bone fracture is a continual concern for people with osteoporosis. Until recently, osteoporosis patients were treated with either antiresorptive or anabolic medications. Antiresorptive medications help slow bone loss — although they do not stimulate bone formation. Anabolic medications stimulate bone formation — although they can stimulate bone resorption as well.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A new dual-acting drug, romosozumab, combines the benefits of earlier drugs, both increasing bone formation and decreasing bone resorption. Approved by the FDA in 2019, romosozumab builds more bone than any previous osteoporosis drug.
In this video, learn more about why romosozumab is one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.
Advertisement
Advertisement
Cleveland Clinic will offer rapid, pinpoint airborne transport of medications and other medical items
Dedicated committee and surgical fellowship strive for sustainability, energy efficiency, waste reduction
Next-generation mRNA vaccines are among the advancements likely to change healthcare this year
$50 million pledge will help remove sources of lead exposure from Cleveland homes
How to empower caregivers and engage patients in patient safety
Summit to cap off with Annual Top 10 Medical Innovations
The spine surgeon will oversee more than 125 staff physicians in his new role
Merlino rejoins Cleveland Clinic to help execute bold strategic vision